At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TARA ArTara Therapeutics, Inc.
Post-Market Trading 12-24 13:23:15 EST
5.17
+0.02
+0.39%
High5.20
Low5.05
Vol309.18K
Open5.15
D1 Closing5.15
Amplitude2.82%
Mkt Cap177.43M
Tradable Cap150.80M
Total Shares34.32M
T/O1.59M
T/O Rate1.06%
Tradable Shares29.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Protara Therapeutics Closes $100 Million Securities Offering
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.